Böcker i Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy-serien

Immunotherapeutic Strategies for the Treatment of Glioma provides a review of the current state of immunotherapy for primary brain tumors. The topic is of interest to patients, clinicians, and researchers alike, particularly given the recent failure of large clinical trials. This book serves as an overview of the most promising approaches in the field and provides a foundation for considering novel and combination therapies moving forward.The book discusses several types of immunotherapies for glioma, such as peptide, dendritic cell and heat shock protein vaccines; immune checkpoint blockade; myeloid cells as target; oncolytic viruses; and CAR T cell therapy. Additionally, it discusses the mechanisms of immune suppression in patients and immunogenomics.This volume is a valuable source for cancer researchers, oncologists and several members of biomedical field who are interested in novel strategies to fight glioblastoma. Summarizes the work in immunotherapy for glioma to-date, including the available evidence from preclinical studies and clinical trialsReviews the challenges and successes of the most promising strategies for brain tumor immunotherapyProvides a foundation for considering novel and combination therapies moving forward

¿¿ T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation sets out and critically discusses the current clinical and relevant preclinical ¿¿ T cell immunotherapy landscape. In five chapters, field experts discuss the challenges facing ¿¿ T cell oncoimmunotherapy, propose solutions, and map next steps. Particular attention is given to summarizing our understanding of the complex, translationally relevant human ¿¿ T cell biology, the evidence basis for designing ¿¿ T cell combination trials and data-driven perspectives on what is known-and what isn’t-about ¿¿ T cell therapeutic persistence. Various perspectives are provided on how issues of cytotoxic effector function, functional exhaustion, and cytokine addiction can be mitigated using gene engineering. A chapter is dedicated to the systematic review of all ¿¿ T cell immunotherapy trials to date, and the cell therapy products that were used in these trials. The final chapter discusses allograft persistence-enhancement techniques in the context of ¿¿ T cell therapy, covering lymphodepleting chemotherapy and synthetic stealth engineering. ¿¿ T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation gives an updated and comprehensive insight into the current state of ¿¿T cell immunotherapy, which is of interest to existing translational ¿¿ T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ¿¿ T cell immunotherapy in the clinic, or are wishing to familiarize themselves with noncanonical lymphocyte immunotherapy.